Vicarious Surgical Inc. 8-K

What Happened
Vicarious Surgical Inc. (RBOT) filed an 8-K on March 9, 2026 announcing it issued a press release with results for the fiscal year and fourth quarter ended December 31, 2025 (press release furnished as Exhibit 99.1). Separately, the company disclosed that the New York Stock Exchange notified it on March 3, 2026 that trading in its common stock had been immediately suspended and that the NYSE commenced delisting proceedings because the company’s average global market capitalization fell below the $15,000,000 continued listing standard.

Key Details

• Press release announcing fiscal year and Q4 results for the period ended December 31, 2025 was issued March 9, 2026 (Exhibit 99.1).
• NYSE notified the company on March 3, 2026 of immediate trading suspension and delisting proceedings under Section 802.01B (average global market cap below $15,000,000).
• The company decided not to appeal the NYSE delisting determination.
• Quotation on the OTCID tier began March 4, 2026 under the symbol “RBOT”; the company has applied to upgrade to the OTCQB venture market.
• The company cautioned there is no assurance of continued trading on OTC markets, of broker-dealers maintaining quotes, or of sufficient trading volume; the filing contains standard forward-looking statement disclaimers.

Why It Matters
For investors, the NYSE suspension and impending delisting materially affect liquidity, price discovery and institutional participation—shares moving to OTCID typically trade with wider spreads and less volume. While the company has moved to an OTC quotation (RBOT) and seeks OTCQB status, the filing warns there is no guarantee of sustained trading or broker-dealer quoting. The press release contains the company’s reported earnings and financial details for FY2025/Q4; investors should review that release for the results and consider the reduced market listing when assessing the stock.